Evidence map›Paper›PMID 37772231›Full record

ArticleCureus2023

Boric Acid Exhibits Anticancer Properties in Human Endometrial Cancer Ishikawa Cells.

Ayşe Çakır Gündoğdu, Neziha Senem Arı, Asiye Höbel, Gülnihal Şenol, Ömer Eldiven, Fatih Kar

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ayşe Çakır GündoğduHistology and Embryology, Kütahya Health Sciences University, Kütahya, TUR.
Neziha Senem ArıHistology and Embryology, Kütahya Health Sciences University, Kütahya, TUR.
Asiye HöbelHistology and Embryology, Kütahya Health Sciences University, Kütahya, TUR.
Gülnihal ŞenolHistology and Embryology, Kütahya Health Sciences University, Kütahya, TUR.
Ömer EldivenHistology and Embryology, Kütahya Health Sciences University, Kütahya, TUR.
Fatih KarMedical Biochemistry, Kutahya University of Health Sciences, School of Medicine, Kütahya, TUR.
Universidad CES · COKutahya Saglik Bilimleri UniversitesiUniversity of Health Sciences Antigua · AG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study aims to explore the potential anti-cancer properties of boric acid (BA) in human endometrial cancer Ishikawa cells by assessing its influence on cell viability, apoptosis, oxidative stress, and inflammatory responses. Methods The impact of BA at concentrations ranging from 2.5 to 100 mM on cell viability was assessed in Ishikawa cells and normal fibroblast L929 cells (used as the control) through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Spectrophotometric measurements were performed to determine the total oxidant status (TOS) and total antioxidant status (TAS) in BA-treated cells, and the oxidative stress index (OSI) was calculated. The enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of cytochrome c and caspase 3, both of which are constituents of the extrinsic apoptotic pathway. Furthermore, changes in the concentrations of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1beta (IL-1β) in the cells were analyzed using ELISA and immunofluorescence staining. Results The exposure of Ishikawa cells to BA for 24 hours led to a dose-dependent decline in cell viability, with an IC

Indexed as

apoptosisboric acidendometrial cancerinflammationoxidative stress

Identifiers

PMID37772231
PMCPMC10531031
OpenAlexW4386213033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.